Angel Reyes Joins Altasciences as General Manager of CDMO Services
Altasciences is excited to announce the appointment of Angel Reyes as the General Manager of Contract Development and Manufacturing Organization (CDMO) Services. With over a decade of experience in management and supervisory roles for manufacturing operations and supply chains, Angel brings a wealth of knowledge and expertise to Altasciences. Previously serving as the Director of Operations at Catalent, Angel has demonstrated a strong commitment to compliance and cGMP policies.
As the General Manager, Angel will oversee the day-to-day operations in analytical and manufacturing services, as well as manage client relations. His scientific background, coupled with his ability to find innovative solutions and improve operations, will undoubtedly make a significant impact on the organization. Ben Reed, Executive General Manager of CDMO Services at Altasciences, expressed confidence in Angel's abilities and highlighted his valuable contributions to the CDMO team.
Altasciences is an integrated drug development solution company that offers pharmaceutical and biotechnology companies a comprehensive range of services, including preclinical and clinical pharmacology studies, formulation, manufacturing, and analytical services. With a focus on supporting faster and more informed early drug development decisions, Altasciences has been a trusted partner for over 25 years. Their customizable, full-service solutions help sponsors bring better drugs to market efficiently.
For more information about Altasciences and their services, visit their website at altasciences.com.
The Impact of Angel Reyes' Appointment on New Businesses in the Pharmaceutical Sector
The recent appointment of Angel Reyes as the General Manager of Contract Development and Manufacturing Organization (CDMO) Services at Altasciences could potentially have a significant impact on new businesses in the pharmaceutical and biotechnology sectors. Reyes' vast experience and commitment to compliance and cGMP policies could set a new standard in the industry, pushing emerging businesses to elevate their operations to meet this benchmark.
Reyes' role in overseeing analytical and manufacturing services could also influence the way new businesses structure their operations. His approach to managing client relations and improving operations through innovative solutions could serve as a model for startups looking to optimize their processes.
Moreover, Altasciences' commitment to supporting faster and more informed early drug development decisions could encourage new businesses to adopt a similar approach. By offering comprehensive services, from preclinical and clinical pharmacology studies to formulation, manufacturing, and analytical services, Altasciences demonstrates a successful business model that new businesses could emulate.
In conclusion, the appointment of Angel Reyes could influence new businesses in the pharmaceutical and biotechnology sectors by setting high industry standards and providing a successful business model to follow.